Poseida Therapeutics Inc at HC Wainwright Cell Therapy Virtual Conference Transcript
Good morning, and thanks for joining us at H.C. Wainwright's Cell Therapy Conference to have a conversation with Mr. Mark Gergen, the Chief Executive Officer of Poseida Therapeutics. Poseida is a clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies to treat cancers and the rare genetic diseases.
The company is leveraging its proprietary platforms, including piggyBac, Cas-CLOVER, and the nanoparticle delivery technologies for pipeline development. Poseida currently has two clinical-stage allo CAR-T candidates and a number of preclinical in vivo gene therapy programs.
To discuss these programs and to learn about the company's development strategy in 2023 and beyond, I'd like to invite Mark to this fireside chat. Good morning, Mark.
Good morning, Arthur. Thanks for having us at the conference today.
Yeah, glad to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |